Itraconazole is known to be effective in aspergillosis treatment, particularly of the respiratory tract, however failures do occur, and therapy for invasive aspergillosis remains a matter of conjecture. Although terbinafine is used as systemic therapy against dermatophytes, it has an antifungal activity against a broad spectrum of medically important filamentous fungi. The aim of our study was to examine the in vitro activity of terbinafine, itraconazole and their combination against clinical and environmental isolates of Aspergillus species: A. fumigatus (19), A. niger (6), A. flavus (3), A. glaucus (1), A. clavatus (1), A. candidus (1) and A. terreus (1) using a checkerboard method with RPMI medium buffered with MOPS. MIC 90 for itraconazole was 1 micro g/ml and for terbinafine was 4 micro g/ml. The fractional inhibitory concentrations (FIC) were: (Table too large for electronic database. See abstract book for table.) These preliminary in vitro results showed an important synergistic activity specially against A. fumigatus. No antagonism was observed. Although further in vivo and in vitro studies must be performed, terbinafine alone or in combination with itraconazole may have potential in aspergillosis therapy.
Full conference title:
38th Interscience Conference on Antimicrobial Agents and Chemotherapy
- ICAAC 38th